Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
DaxibotulinumtoxinA for Injection is a novel botulinum toxin type A for which Revance is currently seeking FDA approval for the treatment of glabellar lines (GL). It is generally accepted that as age increases, the efficacy of botulinum toxin decreases. This has been demonstrated in multiple studies with current aesthetic botulinum toxin products. The subgroup analysis from the Phase 3 SAKURA clinical program for glabellar lines (GL), which is the largest program for GL with over 3,000 subjects, examined the effects of DaxibotulinumtoxinA for Injection on GL among female subjects ages: 18-45, >45-55, and >55. A further analysis was performed on female subjects <65 and ≥65 years. The data from the analysis showed that DaxibotulinumtoxinA for Injection was safe, effective and delivered a median time to loss of none or mild of at least 24 weeks across all female age groups.
“We look forward to sharing the positive results from our Phase 3 SAKURA program at this year’s Aesthetic Meeting,” said
The abstracts are available online via the ASAPS website at surgery.org.
Title: DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program (SAKURA)
Authors and Affiliations:
Glynis Ablon, Ava Shamban, Susan Weinkle, Jessica Brown, Yan Liu, Ablon Skin Institute, Manhattan Beach, CA; Ava MD, Santa Monica & Beverly Hills, CA; Susan H. Weinkle, MD, Bradenton, FL; Revance Therapeutics, Newark, CA
Resilient Hyaluronic Acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
Any statements in this press release that are not statements of historical fact, including statements related to our ability to obtain, and the timing relating to the anticipated approval of DaxibotulinumtoxinA for Injection in glabellar lines; the results of the SAKURA Phase 3 clinical program; development of a biosimilar to BOTOX®; statements about our business strategy, timeline, other goals and our plans and prospects; and potential benefits of our drug product candidates and our technologies, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties relate, but are not limited to: the results, timing, costs, and completion of our research and development activities and regulatory approvals, including delays in the approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end user demand for our products, commercialization efforts, business operations, clinical trials and other aspects of our business; our ability to manufacture supplies for our product candidates; the uncertain clinical development process; the risk that clinical trials may not have an effective design or generate positive results; the applicability of clinical study results to actual outcomes; our ability to successfully compete with other treatments and therapies; our ability to achieve, and the rate and degree of commercial acceptance and the market, size and growth potential of our drug product candidates, if approved; our ability to successfully commercialize our drug product candidates, if approved, and the timing and cost of commercialization activities; our ability to obtain and maintain regulatory approval of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; our ability to develop sales and marketing capabilities; the status of commercial collaborations; our ability to obtain funding for our operations; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in our periodic filings with the
Jenifer Slaw, 347-971-0906
Nadine Tosk, 504-453-8344